KR-20260062625-A - Polydopamine catalase conjugate and its manufacturing method
Abstract
The present invention relates to a polydopamine catalase conjugate capable of exhibiting a cell proliferation effect in a hypoxic environment by coating the surface of polydopamine in a form conjugated with catalase, and a method for manufacturing the same. The technical gist of the present invention is a polydopamine catalase conjugate characterized by comprising polydopamine and catalase. The present invention also has as a technical gist a method for manufacturing a polydopamine catalase conjugate, characterized by comprising the steps of: preparing polydopamine nanoparticles; preparing catalase; and completing a polydopamine catalase conjugate by coating the surface of the prepared polydopamine with the prepared catalase in a conjugated structure.
Inventors
- 김수환
- 김민진
- 최수미
Assignees
- 동아대학교 산학협력단
Dates
- Publication Date
- 20260507
- Application Date
- 20241029
Claims (6)
- A polydopamine catalase conjugate characterized by containing polydopamine and catalase.
- In paragraph 1, The above polydopamine is Polydopamine catalase conjugate characterized by having nanoparticles that enable penetration into the interior of a cell.
- In paragraph 2, The above catalase A polydopamine catalase conjugate characterized by being bonded and coated to the surface of the above-mentioned polydopamine.
- Step of preparing polydopamine nanoparticles; Steps for preparing catalase; and A method for manufacturing a polydopamine catalase conjugate characterized by comprising the step of completing a polydopamine catalase conjugate by coating the surface of the prepared polydopamine with a structure in which the prepared catalase is bonded.
- In paragraph 4, The step of preparing the above-mentioned polydopamine is A step of preparing a buffer solution by mixing secondary distilled water, an ethanol solution, Tris hydrochloric acid, and sodium hydroxide; A step of mixing dopamine hydrochloride into a prepared buffer solution and inducing the self-polymerization of dopamine through reaction with air while stirring at room temperature to form polydopamine; A step of centrifuging self-polymerized polydopamine at low temperature; A step of adding distilled water to centrifuged polydopamine and washing the polydopamine while centrifuging at a low temperature; and A method for manufacturing a polydopamine catalase conjugate characterized by comprising the step of freezing washed polydopamine and then freezing-hardening it to complete the polydopamine nanoparticles.
- In paragraph 4, The step of completing the above polydopamine catalase conjugate is A step of preparing a catalase solution by mixing catalase enzyme with distilled water; A step of preparing a polydopamine dispersion solution by mixing the finished polydopamine with distilled water and then ultrasonically treating it; A step of mixing the above polydopamine dispersion solution and the above catalase solution in a volume ratio of 20:1; A step of stirring the mixed polydopamine catalase mixture at room temperature; A step of centrifuging the stirred polydopamine catalase mixture at a low temperature to precipitate the polydopamine catalase conjugate and then removing the supernatant; and A method for manufacturing a polydopamine catalase conjugate characterized by comprising the step of completing the polydopamine catalase conjugate by washing the polydopamine catalase conjugate, from which the supernatant has been removed, with distilled water multiple times to remove unreacted catalase.
Description
Polydopamine catalase conjugate and its manufacturing method The present invention relates to a polydopamine catalase conjugate comprising polydopamine and catalase and a method for manufacturing the same. Catalase is an enzyme used to decompose hydrogen peroxide into water and oxygen. It is present in most organic matter that inhabits oxygenated environments, and it is known that organisms prevent oxidative damage within the organism by removing lethal reactive oxygen species through dehydrogenation reactions utilizing catalase. This catalase is known to have the highest catalytic activity among enzymes. In other words, catalase is known to break down millions of hydrogen peroxide molecules per second per molecule to produce oxygen and water. Recently, active research and development is being conducted on technology to manufacture particles with oxygen-releasing capabilities by applying catalase, which decomposes hydrogen peroxide molecules to release oxygen. Meanwhile, most conventional technologies being researched and developed to manufacture particles with oxygen-releasing capabilities utilize a method of releasing oxygen by directly injecting hydrogen peroxide. However, the method of releasing oxygen by directly injecting hydrogen peroxide, as in conventional technology, has the problem that the toxicity of hydrogen peroxide to cells not only significantly reduces cell survival rates but also has adverse effects that inhibit cell migration and proliferation. Therefore, research and development are needed on a composition that is expected to reduce toxicity to cells and increase cell survival rates in a hypoxic environment and promote cell migration and proliferation by using catalase to remove active oxygen and release oxygen without directly adding hydrogen peroxide. FIG. 1 is a schematic diagram illustrating the structure of a polydopamine catalase conjugate according to an embodiment of the present invention. FIG. 2 is a flowchart illustrating a method for manufacturing a polydopamine catalase conjugate according to an embodiment of the present invention. FIG. 3 is a flowchart illustrating the polydopamine preparation step of a method for manufacturing a polydopamine catalase conjugate according to an embodiment of the present invention. FIG. 4 is a flowchart illustrating the polydopamine catalase conjugation step of a method for manufacturing a polydopamine catalase conjugate according to an embodiment of the present invention. Figure 5 is a graph comparing spectral data from a Fourier transform infrared spectrometer for polydopamine according to an embodiment of the present invention with that of dopamine. Figure 6 is a graph showing the hydrogen peroxide release amount over time for a polydopamine catalase conjugate according to an embodiment of the present invention, compared with that of polydopamine. Figure 7 is a photograph taken of the state in which oxygen bubbles are generated to confirm the oxygen release effect of the polydopamine catalase conjugate according to an embodiment of the present invention. Figure 8 is an image observed with a fluorescence microscope to compare the cell viability of a polydopamine catalase conjugate according to an embodiment of the present invention with that of polydopamine. Figure 9 is a graph showing the cell viability of a polydopamine catalase conjugate according to an embodiment of the present invention compared with that of polydopamine. Figure 10 is an image observed with a fluorescence microscope to compare the cell viability of a polydopamine catalase conjugate according to an embodiment of the present invention under hypoxic conditions with that of polydopamine. Figure 11 is a graph showing the cell viability of a polydopamine catalase conjugate according to an embodiment of the present invention under hypoxic conditions compared with that of polydopamine. Figure 12 is an image observed with a fluorescence microscope to compare the cell proliferation rate of a polydopamine catalase conjugate according to an embodiment of the present invention under hypoxic conditions with that of polydopamine. Figure 13 is a graph showing the cell proliferation rate of a polydopamine catalase conjugate according to an embodiment of the present invention under hypoxic conditions compared with that of polydopamine. Figure 14 is an image showing the results of comparing the wound closing effect of a polydopamine catalase conjugate according to an embodiment of the present invention under hypoxic conditions with that of polydopamine. Figure 15 is a graph comparing the wound closing effect of a polydopamine catalase conjugate according to an embodiment of the present invention under hypoxic conditions with that of polydopamine. The present invention relates to a polydopamine catalase conjugate (PDA@CAT) comprising polydopamine (PDA) and catalase (CAT) and a method for manufacturing the same. In particular, a major feature of the polydopamine catalase conjugate and the